VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 7, 2013) - Eternity Healthcare (the "Company") (OTCBB:ETAH) announced that Dr. Hassan Salari, President & CEO will be presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference will take place February 11-12 at the Waldorf-Astoria in New York City. Eternity Healthcare will be presenting to the attendees from industry, financial and social media sectors. The presentation will be webcast at the followings, on Monday February 11 at 3:30. The URL for webcast is: http://www.veracast.com/webcasts/bio/ceoinvestor2013/43122224.cfm
"This is an excellent opportunity for us to present our company to several hundred biotechnology and pharmaceutical executives which may lead to several partnership on the use of our product in delivery of medicine to the patients," said Dr. Salari, President & CEO. "Further the forum is set to introduce several of our upcoming pre-filled medications to the audience," added Dr. Salari.
Eternity Healthcare has also launched its new versatile and dynamic website which provides detailed information on the Company and its products. Visit the website at www.eternityhealthcare.com.
ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. This year's conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing from seasoned industry executives and analysts. New this year, a special track of 25 high-caliber private companies will be presenting at the event, and plenary sessions will address timely business issues and industry trends. Attendees can expect many opportunities to schedule one-on-one meetings as well as numerous networking opportunities. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. Complimentary registration is available to qualified institutional (buy and sell-side), private equity, and venture investors and can be accessed here: http://www.bio.org/events/conferences/bio-ceo-investor-registration
ABOUT ETERNITY HEALTHCARE
Eternity Healthcare is a medical device company specialized in designing, developing and commercialization of Needle-free drug delivery technologies and other medical devices. Further the Company is introducing a number of prefilled pharmaceutical drugs using needle-free injection system. The Company's lead technology is a novel needle-free device known as "Comfort-in™", suitable for delivering insulin, growth hormone, vitamins, vaccines and vast number of other drugs. Comfort-in has received approval in Europe by European regulatory bodies, in Canada, in Korea and submitted for approval by the FDA.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the United States Securities Act of 1933, as amended, and U.S. securities Exchange Act of 1934, as amended. Statements other than statements of historical facts, included in this press release that address activities, events or projected revenue, as well as other financial projections, are forward-looking statements and forward-looking information. Investors should consult their financial advisors and further visit the Company's quarterly and annual fillings prior to getting involved with the Company's securities. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.